Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies

NCT00433745 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00433745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00433745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
November 30, 2009
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic myeloid leukemia (cml), myelodysplastic syndrome